LHCGR

luteinizing hormone/choriogonadotropin receptor, the group of Glycoprotein hormone receptors

Basic information

Region (hg38): 2:48686774-48755730

Previous symbols: [ "HHG" ]

Links

ENSG00000138039NCBI:3973OMIM:152790HGNC:6585Uniprot:P22888AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • familial male-limited precocious puberty (Supportive), mode of inheritance: AD
  • Leydig cell hypoplasia, type 1 (Strong), mode of inheritance: AR
  • familial male-limited precocious puberty (Strong), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Leydig cell hypoplasia type I; Leydig cell hypoplasia type II; Luteinizing hormone resistance, female; Precocious puberty, maleAREndocrine; Genitourinary; OncologicIn mild forms of LCH, the disorder may not be clinically recognized early, and exogenous testosterone can result in normal virilization; In Precocious puberty, male, medical therapy (eg, with combined spironolactone and testolactone) has been reported as beneficial; Surveillance for related neoplasms (eg, testicular neoplasms) may allow prompt diagnosis and treatmentEndocrine; Genitourinary; Oncologic184390; 6792847; 3557461; 3812586; 2492636; 7692306; 7719343; 7581384; 8559204; 8923827; 9703386; 9817592; 10580072; 10714363; 10704433; 11391350; 11857565; 19129711; 21060208; 21683950; 21720050; 22369774; 22931948
Both germline and somatic variants have been described

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the LHCGR gene.

  • not provided (13 variants)
  • Gonadotropin-independent familial sexual precocity (4 variants)
  • Leydig cell agenesis (3 variants)
  • LHCGR-related disorder (1 variants)
  • Precocious puberty in males (1 variants)
  • Gonadotropin-independent familial sexual precocity;Leydig cell agenesis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the LHCGR gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
12
clinvar
4
clinvar
19
missense
7
clinvar
6
clinvar
52
clinvar
6
clinvar
2
clinvar
73
nonsense
4
clinvar
3
clinvar
7
start loss
0
frameshift
1
clinvar
1
inframe indel
1
clinvar
4
clinvar
1
clinvar
6
splice donor/acceptor (+/-2bp)
1
clinvar
2
clinvar
3
splice region
1
3
1
5
non coding
16
clinvar
17
clinvar
35
clinvar
68
Total 14 11 75 35 42

Highest pathogenic variant AF is 0.0000592

Variants in LHCGR

This is a list of pathogenic ClinVar variants found in the LHCGR region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
2-48686803-C-A Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Uncertain significance (Jan 13, 2018)897354
2-48686892-T-C Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Uncertain significance (Jan 13, 2018)898509
2-48686950-G-T Leydig cell agenesis • Gonadotropin-independent familial sexual precocity Uncertain significance (Jan 13, 2018)898510
2-48686973-A-G Leydig cell agenesis • Gonadotropin-independent familial sexual precocity • Hypergonadotropic hypogonadism Uncertain significance (Jan 12, 2018)336445
2-48686987-T-C Leydig cell agenesis • Gonadotropin-independent familial sexual precocity Uncertain significance (Jan 12, 2018)898511
2-48687120-A-T Gonadotropin-independent familial sexual precocity • Hypergonadotropic hypogonadism • Leydig cell agenesis Conflicting classifications of pathogenicity (Jan 12, 2018)336446
2-48687144-T-A Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Uncertain significance (Jan 13, 2018)895518
2-48687162-C-T Leydig cell agenesis • Gonadotropin-independent familial sexual precocity • Hypergonadotropic hypogonadism Benign/Likely benign (Jan 13, 2018)336447
2-48687169-A-G Hypergonadotropic hypogonadism • Leydig cell agenesis • Gonadotropin-independent familial sexual precocity Benign (May 13, 2021)336448
2-48687185-G-A Leydig cell agenesis • Gonadotropin-independent familial sexual precocity Conflicting classifications of pathogenicity (Jan 12, 2018)896920
2-48687254-G-A Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Uncertain significance (Jan 12, 2018)896921
2-48687283-A-G Leydig cell agenesis • Gonadotropin-independent familial sexual precocity Uncertain significance (Jan 12, 2018)896922
2-48687314-G-T Gonadotropin-independent familial sexual precocity • Leydig cell agenesis • Hypergonadotropic hypogonadism Uncertain significance (Jan 12, 2018)336449
2-48687337-C-T Gonadotropin-independent familial sexual precocity • Leydig cell agenesis • Hypergonadotropic hypogonadism Benign (May 13, 2021)336450
2-48687397-A-T Leydig cell agenesis • Hypergonadotropic hypogonadism • Gonadotropin-independent familial sexual precocity Uncertain significance (Jan 13, 2018)336451
2-48687415-GT-G Gonadotropin-independent familial sexual precocity • Leydig cell agenesis • Hypergonadotropic hypogonadism Likely benign (Jun 14, 2016)336452
2-48687424-A-G Gonadotropin-independent familial sexual precocity • Hypergonadotropic hypogonadism • Leydig cell agenesis Uncertain significance (Jan 13, 2018)336453
2-48687476-C-G Leydig cell agenesis • Hypergonadotropic hypogonadism • Gonadotropin-independent familial sexual precocity Benign (Jun 26, 2018)336454
2-48687505-A-G Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Uncertain significance (Jan 12, 2018)898585
2-48687515-A-G Leydig cell agenesis • Gonadotropin-independent familial sexual precocity Uncertain significance (Jan 12, 2018)898586
2-48687549-A-G Gonadotropin-independent familial sexual precocity • Hypergonadotropic hypogonadism • Leydig cell agenesis Benign (Aug 12, 2018)336455
2-48687566-G-A Leydig cell agenesis • Hypergonadotropic hypogonadism • Gonadotropin-independent familial sexual precocity Benign/Likely benign (Nov 08, 2018)336456
2-48687643-A-AT Likely benign (Oct 18, 2020)1189231
2-48687675-A-C Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Benign/Likely benign (Jan 12, 2018)895594
2-48687690-G-A Hypergonadotropic hypogonadism • Gonadotropin-independent familial sexual precocity • Leydig cell agenesis Conflicting classifications of pathogenicity (Jan 12, 2018)336457

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
LHCGRprotein_codingprotein_codingENST00000294954 11123453
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
5.30e-80.9621256910571257480.000227
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.1633503590.9760.00001824543
Missense in Polyphen110120.060.916211604
Synonymous-0.04191411401.000.000007261398
Loss of Function2.021627.40.5840.00000142353

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003580.000358
Ashkenazi Jewish0.0003970.000397
East Asian0.000.00
Finnish0.0001850.000185
European (Non-Finnish)0.0002910.000290
Middle Eastern0.000.00
South Asian0.0001310.000131
Other0.0004900.000489

dbNSFP

Source: dbNSFP

Function
FUNCTION: Receptor for lutropin-choriogonadotropic hormone (PubMed:11847099). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099). {ECO:0000269|PubMed:11847099}.;
Disease
DISEASE: Familial male precocious puberty (FMPP) [MIM:176410]: In FMPP the receptor is constitutively activated. {ECO:0000269|PubMed:11134146, ECO:0000269|PubMed:11391350, ECO:0000269|PubMed:7629248, ECO:0000269|PubMed:7692306, ECO:0000269|PubMed:7714085, ECO:0000269|PubMed:7757065, ECO:0000269|PubMed:8281137, ECO:0000269|PubMed:8829636, ECO:0000269|PubMed:8929952, ECO:0000269|PubMed:9467560, ECO:0000269|PubMed:9661624}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Luteinizing hormone resistance (LHR) [MIM:238320]: An autosomal recessive disorder characterized by unresponsiveness to luteinizing hormone, defective sexual development in males, and defective follicular development and ovulation, amenorrhea and infertility in females. Two forms of the disorder have been defined in males. Type 1 is a severe form characterized by complete 46,XY male pseudohermaphroditism, low testosterone and high luteinizing hormone levels, total lack of responsiveness to luteinizing and chorionic gonadotropin hormones, lack of breast development, and absent development of secondary male sex characteristics. Type 2, a milder form, displays a broader range of phenotypic expression ranging from micropenis to severe hypospadias. {ECO:0000269|PubMed:12050206, ECO:0000269|PubMed:15372531, ECO:0000269|PubMed:15472221, ECO:0000269|PubMed:19551906, ECO:0000269|PubMed:7719343, ECO:0000269|PubMed:8559204, ECO:0000269|PubMed:9215288, ECO:0000269|PubMed:9514160, ECO:0000269|PubMed:9626144, ECO:0000269|PubMed:9626653}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Calcium signaling pathway - Homo sapiens (human);Prolactin signaling pathway - Homo sapiens (human);Neuroactive ligand-receptor interaction - Homo sapiens (human);Ovarian steroidogenesis - Homo sapiens (human);Intracellular Signalling Through LHCGR Receptor and Luteinizing Hormone/Choriogonadotropin;Peptide GPCRs;Ovarian Infertility Genes;GPCRs, Class A Rhodopsin-like;Signaling by GPCR;Signal Transduction;G alpha (s) signalling events;Hormone ligand-binding receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;GPCR downstream signalling;Arf6 signaling events (Consensus)

Recessive Scores

pRec
0.426

Intolerance Scores

loftool
0.283
rvis_EVS
0.36
rvis_percentile_EVS
74.63

Haploinsufficiency Scores

pHI
0.130
hipred
N
hipred_score
0.410
ghis
0.441

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.668

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Lhcgr
Phenotype
nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; renal/urinary system phenotype; skeleton phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; normal phenotype; reproductive system phenotype; growth/size/body region phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; cellular phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype;

Zebrafish Information Network

Gene name
lhcgr
Affected structure
postovulatory follicle
Phenotype tag
abnormal
Phenotype quality
increased amount

Gene ontology

Biological process
G protein-coupled receptor signaling pathway;G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger;adenylate cyclase-activating G protein-coupled receptor signaling pathway;activation of adenylate cyclase activity;phospholipase C-activating G protein-coupled receptor signaling pathway;male gonad development;hormone-mediated signaling pathway;ovulation cycle process;male genitalia development;positive regulation of inositol trisphosphate biosynthetic process;luteinizing hormone signaling pathway;positive regulation of adenylate cyclase activity;cognition;cellular response to gonadotropin stimulus;cellular response to luteinizing hormone stimulus
Cellular component
endosome;plasma membrane;integral component of plasma membrane
Molecular function
luteinizing hormone receptor activity;G protein-coupled peptide receptor activity;choriogonadotropin hormone receptor activity;choriogonadotropin hormone binding